Version 2.1.1.0

Abstract

Grant Number:	1R43CA101377-01
PI Name:	SMITH, DOUGLAS M.
PI Email:	dsmith@aastrom.com
PI Title:
Project Title:	Enhanced Tumor Antigen Priming of Dendritic Cell Vaccine

Abstract: DESCRIPTION (provided by the applicant): Dendritic cells have been shown to initiate, regulate, and direct cytolytic T-cell-mediated immune responses against tumor antigens in human patients. Recent clincal trials have demonstrated induction of clinically significant immune responses against malignant diseases using DCs primed ex vivo with autologous tumor antigens including tumor cell lysates. Emerging evidence indicates that dendritic cells have a specialized capacity to acquire antigens from tumor cells and to "cross-present" these exogenously-acquired antigens in the context of class I MHC molecules for activation of CTL responses. Monoclonal antibodies against defined tumor antigens appear to enhance antigen uptake, processing and presentation by dendritic cells. The overall objective of this Phase I proposal is to demonstrate the feasibility of using new strategies for monoclonal antibody-mediated tumor antigen-loading of dendritic cells (DCs) in the AastromReplicell(TM) perfusion bioreactor system as a means for automated production of completed DC-based vaccines for immunotherapy of ovarian cancer.

Thesaurus Terms:
antigen antibody reaction, antigen presentation, antitumor antibody, dendritic cell, neoplasm /cancer vaccine, vaccine development
MHC class I antigen, cytotoxic T lymphocyte, major histocompatibility complex, monoclonal antibody, ovary neoplasm, tumor antigen
bioreactor, biotechnology, enzyme linked immunosorbent assay, flow cytometry, human subject

Institution:	AASTROM BIOSCIENCES, INC.
	BOX 376
	ANN ARBOR, MI 48105
Fiscal Year:	2003
Department:
Project Start:	01-SEP-2003
Project End:	31-MAR-2004
ICD:	NATIONAL CANCER INSTITUTE
IRG:	ZRG1

---